Daniel Steinberger - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Daniel Steinberger's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Daniel Steinberger
Verified
Senior National Investigative Producer, Full Measure
Washington
Beats
Prison, Marijuana, Congo, Music, Africa
Mechanics
Content
Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients
By Daniel Steinberger Verified, Joseph A. Steiner, Onur Tuncer, Madeleine Hinojos| Journal of Nuclear Medicine Verified Our objective is to explore quantitative imaging markers for early prediction of treatment response in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) undergoing [177Lu]Lu-DOTATATE therapy. By doing so, we aim to enable timely switching to more effective therapies in order to prevent time-resource waste and minimize toxicities.
By Daniel Steinberger Verified| ABC NewsOne Verified It was billed as "O'Reilly vs. Stewart 2012: The Rumble in the Air-Conditioned Auditorium", a debate between powerhouse media personalities hosts Bill O'Reilly and Jon Stewart. It was very much a rumble. There was some yelling, but mostly an honest exchange of ideas, and great laughter for the hosts, the packed crowd at the George Washington University campus in Washington, D.C., and the people who paid $4.95 to see it live streamed on the internet. A portion of the proceeds will go to charity.
Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients
By Daniel Steinberger Verified, Joseph A. Steiner, Onur Tuncer, Madeleine Hinojos| Journal of Nuclear Medicine Verified Our objective is to explore quantitative imaging markers for early prediction of treatment response in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) undergoing [177Lu]Lu-DOTATATE therapy. By doing so, we aim to enable timely switching to more effective therapies in order to prevent time-resource waste and minimize toxicities.
Company Info
Full Measure